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1. WHAT IS KNOWN AND OBJECTIVE {#jcpt13165-sec-0005}
==============================

Although low back pain (LBP) is ranked among the top 5 reasons for visits to a physician in the United States, its management remains challenging. According to 2007 guideline recommendations, the first‐line treatment of LBP typically involves acetaminophen or non‐steroidal anti‐inflammatory drugs (NSAIDs).[^1^](#jcpt13165-bib-0001){ref-type="ref"} While NSAIDs have become the cornerstone of pain management for LBP,[^2^](#jcpt13165-bib-0002){ref-type="ref"} they are associated with serious gastrointestinal, cardiovascular and renal adverse events (AEs) and have been reported to be responsible for 11% of preventable drug‐related hospital admissions.[^3^](#jcpt13165-bib-0003){ref-type="ref"} A public health advisory was issued in 2015 by the US Food and Drug Administration (FDA) stating that NSAIDs should be administered at the lowest effective dose for the shortest duration consistent with individual patient treatment goals.[^4^](#jcpt13165-bib-0004){ref-type="ref"}

Approximately 35% of patients receive skeletal muscle relaxants (SMRs) for treatment of acute LBP; though effective for short‐term relief, they are responsible for up to 50% of AEs in this patient population.[^3^](#jcpt13165-bib-0003){ref-type="ref"} Cyclobenzaprine, the most prescribed SMR for the treatment of LBP, can augment the effects of other central nervous system (CNS) depressants and is often misused and abused, according to the US Drug Enforcement Administration.[^5^](#jcpt13165-bib-0005){ref-type="ref"} Somnolence is also a common problem, making it unsafe to drive or operate machinery while on this medication. Indeed, the FDA recommends that for drugs with the potential to impair driving a dedicated driving study be conducted with either over‐the‐road testing or with a driving simulator.[^6^](#jcpt13165-bib-0006){ref-type="ref"}, [^7^](#jcpt13165-bib-0007){ref-type="ref"}, [^8^](#jcpt13165-bib-0008){ref-type="ref"}, [^9^](#jcpt13165-bib-0009){ref-type="ref"}, [^10^](#jcpt13165-bib-0010){ref-type="ref"}

Tolperisone is a centrally acting muscle relaxant that has been available in Europe and Asia for more than 30 years and is currently under investigation in the United States. At doses up to 450 mg/day (150 mg 3 times per day \[TID\]), tolperisone has been shown to treat acute and painful muscle spasm and spasticity in adults and elderly patients. In contrast with other centrally acting muscle relaxants, tolperisone has not been associated with hepatotoxicity, drowsiness or impairment of cognitive function.[^11^](#jcpt13165-bib-0011){ref-type="ref"}, [^12^](#jcpt13165-bib-0012){ref-type="ref"}, [^13^](#jcpt13165-bib-0013){ref-type="ref"}, [^14^](#jcpt13165-bib-0014){ref-type="ref"}, [^15^](#jcpt13165-bib-0015){ref-type="ref"}, [^16^](#jcpt13165-bib-0016){ref-type="ref"}, [^17^](#jcpt13165-bib-0017){ref-type="ref"} In this study in healthy volunteers, we have assessed the impact of tolperisone on driving ability and cognitive functioning compared to placebo and the widely used muscle relaxant cyclobenzaprine.

2. METHODS {#jcpt13165-sec-0006}
==========

2.1. Study design {#jcpt13165-sec-0007}
-----------------

This study (ClinicalTrials.gov number NCT03353922) was a three‐way, randomized, blinded, three‐period crossover study that was conducted at 2 independent research sites in the United States. The protocol and informed consent form were approved by a centralized institutional review board (Chesapeake Institutional Review Board, Columbia, MD) prior to study initiation. All subjects were healthy volunteers who provided written informed consent.

2.2. Subjects {#jcpt13165-sec-0008}
-------------

Eligible subjects were aged 21‐55 years and required to be in general good health. The age range ensured that experienced drivers were enrolled who did not have the known issues and variability of younger or older drivers. In addition, their clinical laboratory assessments and physical examinations demonstrated no relevant clinical abnormalities. Subjects were required to be active drivers (\>10 000 miles per year for the previous 3 years) and to be reasonably capable of driving tasks, as demonstrated by performing no worse than 1 standard deviation (SD) above the mean based on normative data for drivers completing the 20‐minute Country Vigilance Divided Attention (CVDA) driving scenario. Excluding the variability added by less experienced novice drivers is typical for driving studies of this size. Drivers who cannot maintain stable and controlled steering and consistent speed were also excluded as their performance would be judged as impaired and not generalizable to the overwhelming majority of drivers. No psychoactive or sleep‐promoting concomitant medications were permitted. Alcohol use and smoking were not allowed 24 hours prior to admission and throughout the study until discharge from the clinic.

2.3. Study drugs and dosing {#jcpt13165-sec-0009}
---------------------------

Subjects were randomized to 1 of 3 treatment arms and received blinded tablets of tolperisone 150 mg TID, cyclobenzaprine 10 mg TID (acting as a positive control) and placebo TID in 3 separate study periods. Subjects received a total of 7 doses of each study drug. Study drug was administered in each study period in the morning, at midday and at bedtime on days 1 and 2, and in the morning only on day 3. The washout periods exceeded 5 half‐lives for each drug (tolperisone half‐life = 2‐3 hours; cyclobenzaprine half‐life = 18 hours).

2.4. CVDA driving scenario {#jcpt13165-sec-0010}
--------------------------

The CVDA driving scenario is a 100 km, monotonous, 2‐lane highway driving task that includes a secondary visual vigilance task. This scenario has been demonstrated to be sensitive to the effects of low‐dose alcohol, sleepiness, over‐the‐counter antihistamines, muscle relaxants, anxiolytics and benzodiazepine and to the residual effects of a night‐time medication for insomnia (ie zopiclone).[^18^](#jcpt13165-bib-0018){ref-type="ref"}, [^19^](#jcpt13165-bib-0019){ref-type="ref"}, [^20^](#jcpt13165-bib-0020){ref-type="ref"}, [^21^](#jcpt13165-bib-0021){ref-type="ref"} The primary end point of the CVDA scenario is the standard deviation of lateral position (SDLP). This is a measure of an individual\'s ability to maintain lane position. Secondary driving end points derived from the CVDA include parameters related to lane exceedance, speed deviation, excessive speed in corners, divided attention and collisions.

Subjects were screened for simulator sickness and were familiarized with the driving simulation. On day --1, following admission to the clinic, subjects performed a 20‐minute practice drive. At 1 hour after the midday dose of study drug on day 1 (at time to maximum plasma concentration \[T~max~\]), subjects began the 1‐hour CVDA driving scenario. On day 2, to assess next‐day residual effects of the drug, subjects completed the CVDA driving test prior to receiving the morning dose of study drug. On day 3, subjects began the CVDA driving test after the morning dose of study drug to evaluate the effects of repeated dosing.

2.5. Cognitive function test {#jcpt13165-sec-0011}
----------------------------

On days 1‐3 of each study period, the CogScreen (CogScreen LLC; St. Petersburg, FL) symbol digit coding (SDC) test, a computer‐administered digit‐symbol substitution test, was completed prior to the driving simulation. The SDC test provides measures of attention, visual scanning, working memory and speed of information processing.[^19^](#jcpt13165-bib-0019){ref-type="ref"}, [^22^](#jcpt13165-bib-0022){ref-type="ref"}

2.6. Self‐reported measures {#jcpt13165-sec-0012}
---------------------------

On days 1‐3 of each study period, the Karolinska Sleepiness Scale and self‐perceived safety to drive tests were completed to assess subjects' drowsiness and awareness of driving capability. Subjects provided a yes or no answer to whether they felt safe to drive prior to the driving simulation. In addition, after each driving simulation test, subjects answered 2 questions: 1) How well you think you drove for the last 60 minutes? and 2) How motivated did you feel to drive at your best during the last 60 minutes of driving?

Subjects recorded their response to each question by drawing a vertical line on a 100 mm horizontal visual analog scale with anchors for the scale of 'not satisfactory' and 'satisfactory' and 'not motivated' and 'motivated' for the 2 questions.

2.7. Pharmacokinetic sample collection and processing {#jcpt13165-sec-0013}
-----------------------------------------------------

Blood samples for pharmacokinetic analysis were collected before the morning dose of study drug on days 1‐3 and at 15 to 30 minutes after completion of the CVDA driving scenario on days 1 and 3 (approximately 2 hours after the second dose and morning dose of study drug, respectively).

2.8. Sample size and statistical methods {#jcpt13165-sec-0014}
----------------------------------------

This study was designed to test the non‐inferiority of tolperisone relative to placebo, with a cyclobenzaprine test versus placebo to confirm the sensitivity of the driving simulator to detect treatment effects. Formal statistical tests were two‐sided and were tested at the alpha = 0.05 level of significance. Control for multiple comparisons was only included in the analysis of the primary end point. This was accomplished using a hierarchical testing approach with the following sequence of testing: day 1 (single dose), day 2 (residual effect) and day 3 (steady state). Non‐inferiority assessments for tolperisone versus placebo at each time point were to occur if prior comparisons also indicated non‐inferiority. No adjustments to alpha levels were made for either the comparison of cyclobenzaprine to placebo or tolperisone (cyclobenzaprine was included to test for assay sensitivity) or for secondary end points or analyses. For this reason, *P*‐values for cyclobenzaprine comparisons and for secondary end points should be interpreted with caution. For non‐parametric secondary end points (eg lane exceedance), *P*‐values were derived from log‐transformed data. No imputation of missing data was performed.

The primary end point, SDLP, was analysed using a normal theory mixed effects model with fixed effects for sequence, period, and treatment, and a random effect for a subject within the sequence. An unstructured covariance structure and Kenward‐Roger degrees of freedom were used. Pairwise comparisons (hypothesis tests) of differences in the least squares means and 95% confidence intervals on differences were provided for initial dose effect: cyclobenzaprine versus placebo, tolperisone versus placebo and tolperisone versus cyclobenzaprine all following day 1 afternoon dose. Hypothesis tests were also shown for next‐day residual dose effect: cyclobenzaprine versus placebo, tolperisone versus placebo and tolperisone versus cyclobenzaprine all prior to day 2 morning dose. Hypothesis tests were shown for steady state dose effect: cyclobenzaprine versus placebo, tolperisone versus placebo and tolperisone versus cyclobenzaprine all following day 3 morning dose. Pairwise within‐subject differences in SDLP between placebo and historical levels linked to crash risk[^23^](#jcpt13165-bib-0023){ref-type="ref"}, [^24^](#jcpt13165-bib-0024){ref-type="ref"} were compared using McNemar\'s test. These pairwise within‐subject differences in SDLP were also tested for symmetry about zero[^25^](#jcpt13165-bib-0025){ref-type="ref"} using the maximally selected McNemar test. Summary statistics were provided for SDLP for each time point and treatment period.

The relationship between tolperisone and cyclobenzaprine plasma drug levels and driving performance was assessed by correlational analyses.

3. RESULTS AND DISCUSSION {#jcpt13165-sec-0015}
=========================

3.1. Subject disposition and demographics {#jcpt13165-sec-0016}
-----------------------------------------

Of the 35 subjects enrolled in this study\'s intent‐to‐treat population, 31 (88.6%) subjects completed the study and received all planned doses of all 3 study drugs. After day 1 of tolperisone administration, 1 subject prematurely withdrew from the study due to a moderate AE of a Crohn\'s disease flare‐up that was considered by investigators to be unrelated to study drug. Three other subjects withdrew from the study before receiving all 3 study drugs. Two additional subjects were removed from the efficacy analysis population due to a confirmed mistake in dosing in which subjects received cyclobenzaprine instead of tolperisone during period 2. Subject demographics are presented in Table [1](#jcpt13165-tbl-0001){ref-type="table"}.

###### 

Demographic characteristics

+---------------------------+-----------+
| Characteristic            | Overall   |
|                           |           |
|                           | N = 35    |
+===========================+===========+
| Age, y                    |           |
+---------------------------+-----------+
| Mean                      | 35.4      |
+---------------------------+-----------+
| Standard deviation        | 9.5       |
+---------------------------+-----------+
| Median                    | 32        |
+---------------------------+-----------+
| Range                     | 22‐54     |
+---------------------------+-----------+
| Gender, n (%)             |           |
+---------------------------+-----------+
| Male                      | 24 (68.6) |
+---------------------------+-----------+
| Female                    | 11 (31.4) |
+---------------------------+-----------+
| Ethnicity, n (%)          |           |
+---------------------------+-----------+
| Not Hispanic or Latino    | 25 (71.4) |
+---------------------------+-----------+
| Hispanic or Latino        | 10 (28.6) |
+---------------------------+-----------+
| Race, n (%)               |           |
+---------------------------+-----------+
| Black or African American | 17 (48.6) |
+---------------------------+-----------+
| White                     | 17 (48.6) |
+---------------------------+-----------+
| Asian                     | 1 (2.9)   |
+---------------------------+-----------+
| Body mass index, kg/m^2^  |           |
+---------------------------+-----------+
| Mean                      | 25.1      |
+---------------------------+-----------+
| Standard deviation        | 2.9       |
+---------------------------+-----------+
| Median                    | 25.2      |
+---------------------------+-----------+
| Range                     | 18.6‐31.5 |
+---------------------------+-----------+
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3.2. Primary driving scenario end point {#jcpt13165-sec-0017}
---------------------------------------

For the primary end point of SDLP on days 1‐3, there was no significant difference between tolperisone and placebo (all *P *\> .7). Results for tolperisone did not exceed the a priori non‐inferiority criteria of 4.4 cm (ie the magnitude of increase in SDLP seen at 0.05% blood alcohol content). Paired differences between tolperisone and placebo were found to be symmetrical about zero. In contrast, the positive control, cyclobenzaprine, showed significant impairment compared to placebo on day 1 (*P* \< .001), day 2 (*P* \< .001) and day 3 (*P* = .0081) (Figure [1](#jcpt13165-fig-0001){ref-type="fig"}). Again, in contrast to tolperisone, analysis of paired differences between cyclobenzaprine and placebo was found to be asymmetric, with significantly more subjects showing an increase in SDLP under the cyclobenzaprine condition (Figure [2](#jcpt13165-fig-0002){ref-type="fig"}). On days 1 and 2, 58.6% (17/29) and 44.8% (13/29) of subjects receiving cyclobenzaprine had increases in SDLP that exceeded the crash‐risk threshold (ie, an increase of 4.4 cm or more in SDLP).

![SDLP with placebo, tolperisone and cyclobenzaprine on days 1‐3. Day 1 = initial dose effect; day 2 = next‐day residual effect; day 3 = steady state. Day 1: \*Tolperisone versus placebo; *P* = .9967; \*\*Cyclobenzaprine versus placebo; *P* \< .0001. Day 2: \*Tolperisone versus placebo; *P* = .9914; \*\*Cyclobenzaprine versus placebo; *P* \< .0001. Day 3: \*Tolperisone versus placebo; *P* = .7464; \*\*Cyclobenzaprine versus placebo; *P* = .0081](JCPT-45-774-g001){#jcpt13165-fig-0001}

![Within‐subject difference scores in SDLP by treatment. SDLP, standard deviation of lateral position](JCPT-45-774-g002){#jcpt13165-fig-0002}

3.3. Secondary Driving scenario end points {#jcpt13165-sec-0018}
------------------------------------------

Secondary driving end points related to lane position control, speed control, total collisions and excessive speed in corners all showed no significant differences between tolperisone and placebo (Table [2](#jcpt13165-tbl-0002){ref-type="table"}). In contrast, at most time points for the secondary end points, there was a significant difference between cyclobenzaprine and placebo, indicating increased driving impairment. Measures related to divided attention assessed during the driving simulation are shown in Table [3](#jcpt13165-tbl-0003){ref-type="table"}. Generally, there were no differences between groups in the number of correct responses, omission errors or commission errors.

###### 

Secondary driving end points (per protocol population)

                                 Mean (SD)       *P*‐value                               
  ------------------------------ --------------- --------------- --------------- ------- ---------
  Lane exceedance number                                                                 
  Day 1                          2.4 (1.29)      2.4 (1.35)      3.6 (1.43)      .8181   \<.0001
  Day 2                          2.2 (1.42)      2.1 (1.41)      3.2 (1.52)      .8490   \<.0001
  Day 3                          2.4 (1.36)      2.3 (1.44)      2.8 (1.32)      .5237   .0243
  Lane exceedance maximum (cm)                                                           
  Day 1                          54.1 (60.4)     46.9 (78.6)     102.7 (89.8)    .4127   .0119
  Day 2                          36.7 (42.3)     66.2 (217.9)    88.9 (85.4)     .6688   .0238
  Day 3                          43.0 (44.3)     42.0 (34.6)     58.4 (105.1)    .8747   .2466
  Lane exceedance duration (s)                                                           
  Day 1                          28.0 (45.9)     27.4 (38.1)     132.6 (190.0)   .8064   \<.0001
  Day 2                          38.3 (90.2)     20.1 (27.0)     96.7 (161.4)    .2809   .0044
  Day 3                          40.8 (106.3)    31.1 (45.4)     50.7 (94.2)     .9078   .2124
  Average speed (m/s)                                                                    
  Day 1                          26.8 (0.25)     26.8 (0.42)     26.8 (0.37)     .6751   .3871
  Day 2                          26.9 (0.26)     26.8 (0.37)     26.8 (0.40)     .2260   .3967
  Day 3                          26.9 (0.29)     26.8 (0.37)     26.9 (0.38)     .0993   .9354
  Speed deviation                                                                        
  Day 1                          0.77 (0.31)     0.72 (0.34)     1.00 (0.42)     .1533   .0009
  Day 2                          0.74 (0.33)     0.71 (0.34)     0.91 (0.39)     .9490   .0015
  Day 3                          0.75 (0.29)     0.74 (0.44)     0.79 (0.32)     .1637   .1546
  Speeding count                                                                         
  Day 1                          4.0 (6.33)      5.5 (11.63)     9.1 (12.63)     .6587   .0207
  Day 2                          3.9 (9.75)      4.9 (10.62)     8.3 (19.15)     .4231   .0293
  Day 3                          4.6 (8.72)      4.6 (14.48)     7.7 (18.34)     .8748   .0326
  Speeding ratio                                                                         
  Day 1                          0.015 (0.026)   0.024 (0.067)   0.041 (0.065)   .8478   .0272
  Day 2                          0.015 (0.044)   0.023 (0.055)   0.035 (0.070)   .7137   .2160
  Day 3                          0.022 (0.054)   0.022 (0.077)   0.031 (0.079)   .9087   .1078
  Excessive speed in corners                                                             
  Day 1                          118.3 (41.01)   119.9 (42.73)   139.7 (58.14)   .7683   .0148
  Day 2                          100.7 (33.86)   107.3 (34.40)   112.1 (43.35)   .4110   .0982
  Day 3                          108.2 (34.43)   105.6 (33.75)   109.4 (45.47)   .5618   .9845
  Total collisions                                                                       
  Day 1                          0.2 (0.60)      0.0 (0.18)      1.7 (6.06)      .5000   .0938
  Day 2                          0.1 (0.56)      0.0 (0.18)      0.4 (1.17)      .0000   .2500
  Day 3                          0.1 (0.58)      0.0 (0.00)      0.1 (0.55)      .5000   1.0000
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###### 

Measures of divided attention during the driving test (per protocol population)

                                           Mean (SD)     *P*‐value                           
  ---------------------------------------- ------------- ------------- ------------- ------- -------
  Divided attention -- Correct response                                                      
  Day 1                                    19.6 (0.73)   19.4 (0.96)   19.1 (2.02)   .2135   .1537
  Day 2                                    19.7 (0.72)   19.7 (0.70)   19.5 (1.18)   .9753   .5688
  Day 3                                    19.6 (0.57)   19.7 (0.71)   19.2 (2.72)   .5245   .4657
  Divided attention -- Omission errors                                                       
  Day 1                                    0.4 (0.73)    0.5 (0.96)    0.9 (2.02)    .2719   .1196
  Day 2                                    0.3 (0.72)    0.3 (0.69)    0.5 (1.18)    .9806   .6431
  Day 3                                    0.3 (0.55)    0.3 (0.71)    0.4 (1.10)    .0671   .1440
  Divided attention -- Commission errors                                                     
  Day 1                                    0.1 (0.26)    2.4 (13.29)   0.2 (0.40)    .9297   .1903
  Day 2                                    0.1 (0.26)    2.7 (14.04)   0.1 (0.34)    .6941   .6729
  Day 3                                    0.1 (0.41)    2.6 (13.74)   0.1 (0.35)    .5728   .9144
  Reaction time (RT)                                                                         
  Day 1                                    1.33 (0.38)   1.20 (0.30)   1.40 (0.47)   .0155   .1130
  Day 2                                    1.28 (0.38)   1.25 (0.34)   1.32 (0.36)   .4567   .3506
  Day 3                                    1.26 (0.35)   1.23 (0.33)   1.29 (0.37)   .4408   .5461
  Standard deviation of RT                                                                   
  Day 1                                    0.52 (0.24)   0.44 (0.22)   0.51 (0.31)   .0342   .7215
  Day 2                                    0.47 (0.26)   0.38 (0.23)   0.51 (0.27)   .1389   .4247
  Day 3                                    0.40 (0.24)   0.40 (0.25)   0.52 (0.31)   .7368   .0610
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3.4. Cognitive function test {#jcpt13165-sec-0019}
----------------------------

The key assessment on the SDC test, the number of correct responses, showed no significant effect for tolperisone compared to placebo on days 1, 2 or 3. In contrast, there were significantly fewer (*P* \< .05) correct responses for cyclobenzaprine compared to placebo on day 2 (Table [4](#jcpt13165-tbl-0004){ref-type="table"}). In addition, there was no evidence of decline in accuracy with tolperisone compared to placebo. In contrast, there was a significant decline in accuracy with cyclobenzaprine compared to placebo on day 2 (*P* \< .05). Reaction time variability (ie SD of reaction time) on the SDC test was not significantly impacted for tolperisone compared to placebo, but for cyclobenzaprine, it approached significance on day 1 and was significantly higher on day 2; this finding indicated more inconsistency in response speed (*P* \< .05).

###### 

Cognitive function measures on days 1‐3 of each treatment (per protocol population)

                                                               Mean (SD)      *P*‐value                             
  ------------------------------------------------------------ -------------- -------------- -------------- ------- -------
  Symbol digit coding -- Number of correct responses                                                                
  Day 1                                                        66.8 (11.38)   66.4 (10.36)   66.2 (10.35)   .8201   .8536
  Day 2                                                        68.8 (10.26)   69.4 (10.12)   66.3 (10.73)   .1244   .0420
  Day 3                                                        68.8 (10.59)   70.1 (10.35)   67.3 (11.42)   .2106   .4567
  Symbol digit coding -- Accuracy                                                                                   
  Day 1                                                        99.41 (1.35)   99.33 (1.33)   99.18 (1.34)   .8299   .4831
  Day 2                                                        99.46 (1.08)   99.30 (1.46)   98.71 (2.33)   .5387   .0476
  Day 3                                                        99.46 (0.99)   99.24 (2.51)   99.63 (0.74)   .4275   .9073
  Symbol digit coding -- Standard deviation of reaction time                                                        
  Day 1                                                        0.51 (0.14)    0.53 (0.15)    0.56 (0.14)    .3887   .0682
  Day 2                                                        0.51 (0.13)    0.53 (0.16)    0.58 (0.18)    .6483   .0359
  Day 3                                                        0.54 (0.18)    0.48 (0.11)    0.57 (0.33)    .5239   .8917
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3.5. Self‐reported measures {#jcpt13165-sec-0020}
---------------------------

Self‐reported sleepiness, self‐reported motivation and self‐appraised driving performance showed no significant effects for tolperisone compared to placebo, while subjects reported increased sleepiness (day 1), decreased motivation (days 1 and 2) and worse performance on the driving task (days 1 and 2) with cyclobenzaprine (Table [5](#jcpt13165-tbl-0005){ref-type="table"}). In addition to their actual performance on the driving test, the data demonstrate a lack of awareness of driving impairment following dosing with cyclobenzaprine (Table [6](#jcpt13165-tbl-0006){ref-type="table"}). When asked prior to the driving test whether they felt safe to drive during cyclobenzaprine treatment, only 10.3% and 3.4% of subjects reported on days 1 and 2, respectively, that they felt unsafe.

###### 

Self‐reported sleepiness, motivation and self‐reported driving performance on days 1‐3 of each treatment period (per protocol population)

                                              Mean (SD)      *P*‐value                             
  ------------------------------------------- -------------- -------------- -------------- ------- ---------
  Karolinska sleepiness scale score                                                                
  Day 1                                       3.4 (1.99)     3.3 (1.96)     5.6 (2.44)     .4146   \<.0001
  Day 2                                       3.8 (2.11)     4.0 (2.20)     4.2 (2.19)     .4751   .7233
  Day 3                                       3.3 (1.73)     2.9 (1.49)     3.7 (1.86)     .4981   .2477
  Motivation to perform on the driving test                                                        
  Day 1                                       72.4 (24.19)   80.0 (15.59)   61.9 (29.29)   .0551   .0266
  Day 2                                       75.8 (19.67)   78.1 (20.59)   64.0 (28.39)   .3427   .0087
  Day 3                                       70.7 (29.56)   75.1 (28.93)   72.5 (25.01)   .2991   .7059
  Self‐reported driving performance                                                                
  Day 1                                       69.7 (26.12)   69.5 (24.29)   53.8 (31.64)   .9611   .0023
  Day 2                                       72.4 (21.36)   75.2 (21.47)   56.4 (32.13)   .3289   .0006
  Day 3                                       70.5 (25.34)   72.8 (26.48)   63.2 (29.34)   .4879   .1224
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###### 

Self‐reported feeling unsafe to drive on days 1‐3 of each treatment period (per protocol population)

          Placebo                                          Tolperisone   Cyclobenzaprine
  ------- ------------------------------------------------ ------------- -----------------
          Percentage of Subjects Feeling Unsafe to Drive                 
  Day 1   0%                                               3.4%          10.3%
  Day 2   0%                                               3.4%          3.4%
  Day 3   0%                                               0%            0%
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3.6. Pharmacokinetics {#jcpt13165-sec-0021}
---------------------

Tolperisone has a T~max~ of 1 hour and a half‐life of 2‐3 hours. In contrast, cyclobenzaprine has a T~max~ of 7 hours and a long half‐life (\>18 hours); thus, it continued to accumulate over the 3 dosing days. Mean ± SD plasma tolperisone concentrations approximately 2 hours after dosing on day 1, prior to dosing on day 2 and approximately 2 hours after dosing on day 3 were 28.9 ± 26.0, 3.5 ± 3.6 and 20.2 ± 15.7 ng/mL. There were no relationships between tolperisone plasma concentrations on any of the days and measures of driving performance (including the primary end point of SDLP), cognitive functioning or self‐report measures.

3.7. Safety {#jcpt13165-sec-0022}
-----------

Safety was assessed in all subjects who received at least 1 dose of study drug. The incidence of AEs was 36.4% (12/33) in subjects receiving tolperisone, 45.5% (15/33) in subjects receiving cyclobenzaprine and 29.0% (9/31) in subjects receiving placebo. The most common AEs for subjects receiving tolperisone, cyclobenzaprine and placebo, respectively, were somnolence (15.2%, 30.3% and 6.5%), headache (6.1%, 0% and 0%) and dizziness (3.0%, 9.1% and 6.5%). Most AEs were mild or moderate in intensity, and there were no serious AEs. There was 1 severe AE of dizziness reported by a subject receiving cyclobenzaprine.

4. WHAT IS NEW AND CONCLUSIONS {#jcpt13165-sec-0023}
==============================

Psychotropic medicines and those that impact the CNS, including SMRs, have been shown to result in impairment and have an effect on various measures of driving performance.[^19^](#jcpt13165-bib-0019){ref-type="ref"}, [^23^](#jcpt13165-bib-0023){ref-type="ref"}, [^26^](#jcpt13165-bib-0026){ref-type="ref"} LeRoy and Morse[^27^](#jcpt13165-bib-0027){ref-type="ref"} utilized an administrative pharmaceutical claims database in a project for the National Highway Traffic Safety Administration to determine how often various combinations of medications were observed among drivers who experienced a motor vehicle crash compared to those who did not. Their study evaluated the medication use of 33,519 drivers who had motor vehicle crashes (5378 were aged \>50 years) and the medication use of \>100 000 matched controls (3 for each case, matched for age and gender; 16,134 were aged \>50 years). Focusing on driving impairments in drivers aged \>50 years, drivers were 1.2 to 7.5 times more likely to have been involved in a motor vehicle crash if they had taken medications in 35 of 90 medication classes identified as potentially driver‐impairing. They determined that SMRs are associated with a twofold increase in the risk for motor vehicle crashes (odds ratio, 2.09; *P *\< .01). SMRs create greater susceptibility to adverse CNS effects in elderly patients and pose a clear risk that is more broadly appreciated in the medical community, and SMRs continue to be included in the Beers criteria of potentially inappropriate medications in older adults.[^28^](#jcpt13165-bib-0028){ref-type="ref"} SMRs are poorly tolerated by elderly patients because they cause anticholinergic and other AEs related to their mixed pharmacological properties, frequently resulting in somnolence and weakness.[^29^](#jcpt13165-bib-0029){ref-type="ref"}

Given the effects of SMRs on driving ability and their widespread use (in particularly cyclobenzaprine) in the treatment of LBP, the healthcare community has prioritized the need to develop an effective therapeutic option that is not associated with sleepiness, somnolence and driving impairment. This study demonstrated that tolperisone (150 mg TID) did not impair driving performance based on 3 criteria: (1) driving performance (ie SDLP, a validated driving performance measure) was not statistically different from placebo following dosing on day 1, the morning following the first day of dosing (day 2) or on day 3 at steady state; (2) under all 3 tolperisone dosing conditions, SDLP did not exceed the upper limit of the 95% confidence interval for the effect of alcohol at 0.05% BAC; and (3) symmetry analysis showed that the distribution of the paired differences between placebo and tolperisone was not asymmetrical around zero (for all 3 tolperisone dosing conditions). Results for secondary driving end points, measures of cognitive functioning and self‐report measures also demonstrated no significant effects of tolperisone compared to placebo at T~max~, on the morning following an evening dose and following repeated dosing. AEs with tolperisone were mild and were not related to driving outcomes. In contrast, patients who received cyclobenzaprine (10 mg TID) as a positive control demonstrated significantly impaired driving performance on most end points compared to placebo.

Once efficacy is established, and tolperisone would represent a novel SMR with the ability to treat patients without the drowsiness associated with other known SMRs and would be an important alternative for the treatment of acute muscle spasms. In patients aged \>65 years, the use of any type of SMR, including cyclobenzaprine, carisoprodol, orphenadrine, baclofen, methocarbamol, tizanidine and metaxalone, has been shown to have a 35% higher likelihood of injury in the 60 days post‐SMR initiation after controlling for confounding medications.[^29^](#jcpt13165-bib-0029){ref-type="ref"} Cyclobenzaprine and other SMRs are associated with driving impairment on various cognitive measures associated with driving.[^8^](#jcpt13165-bib-0008){ref-type="ref"} Although tolperisone needs to be tested directly, the lack of effect on driving performance and other measures of cognitive function demonstrated in the current study suggests that tolperisone could also be used in an elderly population to avoid the adverse CNS effects associated with other SMRs.
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